Opthea Limited's CEO will speak at the Citi 2024 Global Healthcare Conference, discussing retinal disease therapies.
Quiver AI Summary
Opthea Limited, a clinical-stage biopharmaceutical company focused on developing therapies for retinal diseases, including wet age-related macular degeneration, announced that CEO Fred Guerard will engage with investors and participate in a panel at the Citi 2024 Global Healthcare Conference in Miami on December 5, 2024. The panel, titled "Eyes Wide Open on Ophthalmology," will feature Guerard and is scheduled for 1:45 PM ET. Opthea’s lead product, sozinibercept, is currently in pivotal Phase 3 trials aiming to enhance vision treatment outcomes when used with standard therapies. Additional information can be found on the company's website.
Potential Positives
- Opthea Limited is actively engaging with investors by hosting one-on-one meetings and participating in a prominent global healthcare conference, which could enhance its visibility and attract potential funding.
- The CEO's participation in a panel titled "Eyes Wide Open on Ophthalmology" positions the company as a thought leader in the field of ophthalmology, particularly in the treatment of retinal diseases.
- Opthea's lead product candidate, sozinibercept, is in pivotal Phase 3 clinical trials, indicating a significant step towards potentially bringing a novel therapy to market for treating wet AMD and diabetic macular edema.
Potential Negatives
- The announcement focuses on CEO Fred Guerard's participation in a healthcare conference, which may suggest a lack of significant progress or breakthroughs in their clinical trials, potentially disappointing investors looking for more substantial updates.
- While Opthea is developing therapies for progressive retinal diseases, the press release does not provide specific updates on the outcomes or timelines of their clinical trials, leaving uncertainty about the viability of their lead product candidate, sozinibercept.
- The timing of the conference participation before critical clinical trial results may indicate pressure to reassure investors amidst anticipation, potentially signaling underlying concerns about the trials' progression or outcomes.
FAQ
What is the main focus of Opthea Limited?
Opthea Limited develops novel therapies for progressive retinal diseases, particularly wet age-related macular degeneration (wet AMD).
When is the Citi 2024 Global Healthcare Conference?
The conference will take place on December 5, 2024, in Miami, Florida.
Who will represent Opthea at the conference?
Fred Guerard, PharmD, the CEO of Opthea, will represent the company at the conference.
How can I access the conference webcast?
The webcast can be accessed in the "Events & Presentations" section of Opthea's website.
What is Opthea's lead product candidate?
Opthea's lead product candidate is sozinibercept, which is being studied in Phase 3 clinical trials.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OPT Hedge Fund Activity
We have seen 4 institutional investors add shares of $OPT stock to their portfolio, and 7 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VICTORY CAPITAL MANAGEMENT INC removed 840,040 shares (-100.0%) from their portfolio in Q3 2024
- TEACHER RETIREMENT SYSTEM OF TEXAS removed 269,399 shares (-100.0%) from their portfolio in Q3 2024
- BANK OF MONTREAL /CAN/ removed 48,618 shares (-100.0%) from their portfolio in Q3 2024
- JANE STREET GROUP, LLC added 26,632 shares (+inf%) to their portfolio in Q3 2024
- TWIN LAKES CAPITAL MANAGEMENT, LLC added 19,806 shares (+inf%) to their portfolio in Q3 2024
- ROYAL BANK OF CANADA removed 6,000 shares (-100.0%) from their portfolio in Q3 2024
- MILLENNIUM MANAGEMENT LLC removed 3,777 shares (-5.3%) from their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
MELBOURNE, Australia and PRINCETON, N.J., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ:OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that Fred Guerard, PharmD, Chief Executive Officer, will host one-on-one meetings with investors and participate in a panel presentation during the Citi 2024 Global Healthcare Conference on December 5, 2024 in Miami, Florida.
Details are as follows:
| Panel: | Eyes Wide Open on Ophthalmology |
| Presenter: | Frederic Guerard, PharmD, CEO, Opthea |
| Date: | Thursday, December 5, 2024, 1:45 PM ET |
The webcast will be accessible on the “Events & Presentations” section of the Company’s website at http://ir.opthea.com/.
About Opthea
Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Opthea’s lead product candidate, sozinibercept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, NCT04757636 , and ShORe, NCT04757610 ) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.
To learn more, visit our website at www.opthea.com and follow us on X and LinkedIn .
Authorized for release to ASX by Frederic Guerard, PharmD, CEO
Investor Inquiries
PJ Kelleher
LifeSci Advisors, LLC
Email:
[email protected]
Phone: 617-430-7579
Media Inquiries
Silvana Guerci-Lena
NorthStream Global Partners
Email:
[email protected]
Join our email database to receive program updates:
Tel: +61 (0) 3 9826 0399, Email:
[email protected]
Web:
www.opthea.com
Source: Opthea Limited
